LINC 2022: Cost-Effectiveness of Urea Excipient-Based DCBs for CLTI From Femoropopliteal Disease

Watch on Radcliffe Vascular: www.radcliffevascular.com/vid...
In this succinct interview, Prof Michel Reijnen (Rijnstate Hospital, NL) summarises the key-take home messages from a cost-benefit analysis looking at of urea excipient-based drug-coated balloons for chronic limb-threatening ischemia (CLTI) from femoropopliteal disease.
The study showed that this treatment is associated with improved patient outcomes and expected overall cost savings to payers in the respective healthcare systems.
Discussion Points
1. Treatment Aims for CLTI Patients with Femoropopliteal Artery Disease
2. Study Rationale
3. Study Design & Patient Population
4. Key Findings
5. Results Impact on Treatment for Patients with Advanced Disease
6. Take-Home Messages
7. Next Steps
Recorded at LINC 22, Leipzig.
This content is intended for healthcare professionals only.
Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.